Disease · MONDO_0004844
oral mucosa leukoplakia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. oral mucosa leukoplakia. Diseases, record MONDO_0004844. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004844
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Oral idiopathic keratosis, Oral idiopathic leukoplakia, Oral idiopathic white patch, Oral leucoplakia, Oral leukokeratosis, Oral leukoplasia, Oral white patch, Oral white plaque, leukokeratosis, leukokeratosis of oral mucosa, leukoplakia of oral mucosa, leukoplakia of the oral mucosa, oral keratoses, oral keratosis, oral leukoplakia
- Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CALCIPOTRIENE | CHEMBL1200666 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PIOGLITAZONE | CHEMBL595 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMINOLEVULINIC ACID HYDROCHLORIDE | CHEMBL1200582 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AMINOLEVULINIC ACID | CHEMBL601 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IMIQUIMOD | CHEMBL1282 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets57
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/2820 | Drugs and targets |
| MT-ND1 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4535 | Drugs and targets |
| MT-ND2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4536 | Drugs and targets |
| MT-ND3 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4537 | Drugs and targets |
| MT-ND4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4538 | Drugs and targets |
| MT-ND4L | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4539 | Drugs and targets |
| MT-ND5 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4540 | Drugs and targets |
| MT-ND6 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4541 | Drugs and targets |
1 to 10 of 57
See all 57 targetsTrials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00571974 | Treatment of Oral Premalignant Lesions With 5-ALA PDT | Phase 1/2 | 29 | 2012-11-13 | Leukoplakia, Erythroplakia | AMINOLEVULINIC ACID, AMINOLEVULINIC ACID HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT07453472 | Comparison of Topical Photodynamic Therapy With Topical Calcipotriol in Management of Oral Leukoplakia | Phase 3 | 166 | Oral Leukoplakia | CALCIPOTRIENE | Its record names the disease | ClinicalTrials.gov | |
| NCT01238185 | Aspirin Mouthwash in Treating Patients With Oral Leukoplakia | Phase 1 | 40 | Precancerous Condition | ASPIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05727761 | Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia | Phase 2 | 36 | Oral Leukoplakia | METFORMIN, PIOGLITAZONE | Its record names the disease | ClinicalTrials.gov | |
| NCT07210775 | Topical Imiquimod Treatment of Oral Dysplasia | Phase 1/2 | 20 | Oral Dysplasia, Leukoplakia Oral, Leukoplakia | IMIQUIMOD | Its record names the disease | ClinicalTrials.gov | |
| NCT00571558 | Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia | Phase 1 | 15 | Oral Leukoplakia | AMINOLEVULINIC ACID HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05505539 | Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia | Phase 1 | 0 | Oral Leukoplakia | FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Phase I vs Phase II: serious adverse events | 0 of 9 | 0 of 21 | 30 | NCT00571974 |
Source Trial comparisons
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004844
GET https://conductscience.org/api/diseases/v1/MONDO_0004844/targets?page=2